Skip to main content

Public Health Impact of Universal Nirsevimab Prophylaxis: A Multicenter Study on the Reduction of RSV Hospitalizations in Infants in Tuscany, Italy

In brief

Universal nirsevimab linked to 81% fewer infant RSV hospitalizations in Tuscany

Hospitalizations fell from 533 to 104 between RSV seasons, while measures of severe disease and healthcare use also declined; estimated protection against hospitalization was 90%. This retrospective before-and-after study cannot prove nirsevimab caused the drop or establish how long protection lasts, and it highlights the need to protect infants born outside the RSV season.

Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (Q1)
Published
7 November 2026
Study design
Retrospective cohort
Evidence level
Level 3, Low (CEBM 3b)
Authors
Francesco Nieddu, Marina Vignoli, Emanuela Ferraro, Walter Maria Sarli, Claudio Conte, Chiara Demuru, et al.
PMID
42998875
DOI
10.1016/j.ijid.2026.109240

Why clinicians should know about it

  • Picked for Family Practice (paper of the day, 12 November 2026): Real-world infant RSV prophylaxis effectiveness and hospitalization impact

Abstract

BACKGROUND: Nirsevimab is a long-acting monoclonal antibody approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants. Although growing real-world evidence supports its effectiveness, large multicenter studies assessing the population-level impact of universal immunization remain limited. METHODS: We conducted a multicenter retrospective study involving nearly the entire pediatric hospital network in Tuscany, Italy. The public health impact of the universal nirsevimab program was assessed through a pre-post comparison of the 2023-24 and 2024-25 RSV seasons. We evaluated RSV-related hospitalizations, respiratory support requirements and healthcare resource utilization. Nirsevimab effectiveness against RSV-associated hospitalization was estimated using the screening method. FINDINGS: RSV-related hospitalizations declined from 533 cases in 2023-24 to 104 in 2024-25, corresponding to an 80.5% reduction (IRR 0.20, 95% CI 0.16-0.24; p<0.001). Significant reductions were observed across all markers of disease severity, respiratory support requirements and healthcare utilization, including PICU admissions (-87.0%), low-flow oxygen therapy (-78.7%), high-flow oxygen therapy (-81.0%), non-invasive ventilation (-85.0%), bronchodilator use (-82.3%), corticosteroid use (-89.3%), and antibiotic therapy (-84.5%). Infants born outside the RSV season accounted for a substantial proportion of RSV-related hospitalizations and severe disease during the pre-intervention season. Estimated effectiveness against RSV-associated hospitalization was 89.7% (95% CI 85.4-92.7%). A limited number of breakthrough hospitalizations were observed throughout the RSV season without an accumulation towards the end of RSV season, Although these findings do not constitute a formal evaluation of durability of protection, they suggest that protection does not show a substantial decline over the RSV season. INTERPRETATION: Universal nirsevimab immunization was associated with substantial reductions in RSV-related hospitalizations, disease severity, and healthcare resource utilization across Tuscany. This large multicenter study demonstrates a major population-level impact and high real-world effectiveness. Breakthrough hospitalizations occurred throughout the RSV season and did not show a progressive increase across longer post-administration intervals, although the available data do not allow a formal assessment of waning protection. The findings also underscore the important contribution of infants born outside the traditional RSV season to the overall RSV burden, supporting prevention strategies that protect the entire birth cohort.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.